<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715531</url>
  </required_header>
  <id_info>
    <org_study_id>GO30140</org_study_id>
    <nct_id>NCT02715531</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetic variability of
      atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and
      5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU +
      cisplatin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With At Least One Adverse Event</measure>
    <time_frame>From screening to up to 90 days after the last dose of study drug (up to approximately 27 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Atezolizumab (All Arms)</measure>
    <time_frame>Predose (0 hour[h]) and 30min postdose(infusion length=30-60min) on Day 1 of Cycles(Cy) 1 and 3; Predose(0h) on Day 1 of Cy2,4,8 and every 8 Cy until treatment discontinuation(up to 27months); 120days after last dose (Cy length=21-28days; up to 27months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Serum Concentration of Bevacizumab (Arm A, Arm B, and Group D2)</measure>
    <time_frame>Predose (0 h) and 30 minutes (min) postdose (infusion length=30-90 min) on Day 1 of Cycle 1 and 3; at treatment discontinuation (up to 27 months); at 120 days after last dose (Cycle length=21-28 days; up to 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Vanucizumab (Group D1)</measure>
    <time_frame>Predose (0h) and 30min postdose (infusion length=30-90 min) on Day 1 of Cycle 1 and 3; Predose (0h) on Day 1 of Cycles 4,8 and every 8 Cycles until treatment discontinuation(up to 27months); 120 days after last dose (Cycle length=28 days; up to 27months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Oxaliplatin (Arm B and Group E1)</measure>
    <time_frame>Predose (0 h) and 5-10 min before the end of infusion (infusion length=120 min) on Day 1 of Cycles 1 and 3 (Cycle length=21-28 days; up to approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of 5-FU (Arms B and E)</measure>
    <time_frame>Predose (0 h), immediately following bolus administration and 2 hours post-bolus dose on Day 1 of Cycles 1 and 3 (Cycle length=21-28 days; up to approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Cisplatin (Group E2)</measure>
    <time_frame>Predose (0 h) and 5-10 minutes before the end of infusion (infusion length=120 min) on Day 1 of Cycles 1 and 3 (Cycle length=21 days; up to approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of nab-Paclitaxel (Arm C)</measure>
    <time_frame>Predose (0 h), 5-10 minutes before the end of infusion and 1 hour after the end of the infusion (infusion length=35 min) on Day 1 of Cycles 1 and 3 (Cycle length=28 days; up to approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Gemcitabine (Arm C)</measure>
    <time_frame>Predose (0 h), 5-10 minutes before the end of infusion and 1 hour after the end of the infusion (infusion length=35 min) on Day 1 of Cycles 1 and 3 (Cycle length=28 days) (up to approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Best Overall Response as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Best Overall Response as Determined by Immune-Modified RECIST</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Best Overall Response as Determined by HCC-Specific Modified RECIST (Arm D only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response as Determined by RECIST v1.1</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response as Determined by Immune-Modified RECIST</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Objective Response as Determined by HCC-Specific Modified RECIST (Arm D only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response as Determined by RECIST v1.1</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response as Determined by Immune-Modified RECIST</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response as Determined by HCC-Specific Modified RECIST (Arm D Only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free-Survival Duration as Determined by RECIST v1.1</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free-Survival Duration as Determined by Immune-Modified RECIST</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free-Survival Duration as Determined by HCC-Specific Modified RECIST (Arm D Only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Duration</measure>
    <time_frame>Baseline up to study completion or death, whichever occurs first (up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiological Progression as Determined by RECIST v1.1 (Arms A and D only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiological Progression as Determined by Immune-Modified RECIST (Arms A and D only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiological Progression as Determined by HCC-Specific Modified RECIST (Arm D only)</measure>
    <time_frame>Baseline, every 8 weeks (± 1 week) for the first 12 months following Cycle 1 Day 1, and every 12 weeks (± 1 week) thereafter up to study completion (Cycle length=21-28 days; up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Progression as Defined by the Assessment of Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index 8 (FHSI-8) Questionnaire (Arm D only)</measure>
    <time_frame>Baseline up to study completion or symptomatic progression, whichever occurs first (up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab</measure>
    <time_frame>Predose (0 h) on Day 1 of Cycles 1, 2, 3, 4, 8 and every 8 cycles until treatment discontinuation (up to 27 months); at 120 days after last dose (Cycle length =21-28 days; up to 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ATAs to Bevacizumab</measure>
    <time_frame>Predose (0 h) on Day 1 of Cycles 1 and 3; treatment discontinuation (up to 27 months); at 120 days after last dose (Cycle length=21-28 days; up to 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ATAs to Vanucizumab</measure>
    <time_frame>Predose (0 h) on Day 1 of Cycles 1, 3, 4, 8 and every 8 cycles until treatment discontinuation (up to 27 months); at 120 days after last dose (Cycle length=28 days; up to 27 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Arm A (Hepatocellular Carcinoma [HCC])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HCC will receive atezolizumab 1200 milligrams (mg) intravenous (IV) and bevacizumab 15 milligrams per kilogram (mg/kg) IV, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with human epidermal growth factor receptor 2 (HER2) negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) will receive atezolizumab 840 mg IV, bevacizumab 10 mg/kg IV, oxaliplatin 85 milligrams per square meter (mg/m^2) IV, leucovorin 200 mg/m^2 or 400 mg/m^2 IV, and 5-FU (400 mg/m^2 IV bolus, followed by 2400 mg/m^2 continuous IV infusion over 46 [± 1] hours), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered instead of infusional 5-FU and leucovorin, and biologic therapy may be given q3w for participant convenience. The dose of capecitabine will be at the discretion of the investigator (range of 650-1000 mg/m^2 twice daily on Days 1-4 of a 21-day cycle). The dose of atezolizumab will be adjusted to 1200 mg for q3w schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Metastatic Pancreatic Cancer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic pancreatic cancer will receive atezolizumab 840 mg IV q2w starting on Day 1, Cycle 1 (each cycle of 28 days), administration of nab-paclitaxel (125 mg/m^2 IV over 30-40 minutes) followed by gemcitabine (1000 mg/m^2 IV over 30-40 minutes) will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (HCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HCC will be randomized in a ratio of 1:1 to receive either atezolizumab + vanucizumab (Group D1) or atezolizumab + bevacizumab (Group D2). In Group D1, atezolizumab will be administered at 840 mg and vanucizumab at 2000 mg, both IV on a q2w schedule. The cycle length will be 28 days with dosing on Day 1 and Day 15 of each cycle. In Group D2, atezolizumab will be administered at 1200 mg and bevacizumab at 15 mg/kg, both IV on a q3w schedule. The cycle length will be 21 days with dosing on Day 1 of each cycle. Treatment with atezolizumab in combination with vanucizumab or bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (Metastatic Esophageal Cancer [mEC])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with squamous mEC will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab 840 mg IV, oxaliplatin 85 mg/m^2 IV, leucovorin 200 mg/m^2 or 400 mg/m^2 IV, and 5-FU (400 mg/m^2 administered as an IV bolus, followed by 2400 mg/m^2 continuous IV infusion over 46 [± 1] hours), q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab 1200 mg IV followed by cisplatin 80 mg/m^2 IV and 5-FU 800 mg/m^2 IV for 120 hours IV q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU (400 mg/m^2) will be administered as an IV bolus, followed by 2400 mg/m^2 by continuous IV infusion over 46 (± 1) hours, q2w.</description>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
    <arm_group_label>Arm E (Metastatic Esophageal Cancer [mEC])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group D2, and Group E2) or 840 mg q2w (Arm B, Arm C, Group D1, and Groups E1 and E3).</description>
    <arm_group_label>Arm A (Hepatocellular Carcinoma [HCC])</arm_group_label>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
    <arm_group_label>Arm C (Metastatic Pancreatic Cancer)</arm_group_label>
    <arm_group_label>Arm D (HCC)</arm_group_label>
    <arm_group_label>Arm E (Metastatic Esophageal Cancer [mEC])</arm_group_label>
    <other_name>Tecentriq; RO5541267</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group D2) or 10 mg/kg q2w (Arm B).</description>
    <arm_group_label>Arm A (Hepatocellular Carcinoma [HCC])</arm_group_label>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
    <arm_group_label>Arm D (HCC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).</description>
    <arm_group_label>Arm C (Metastatic Pancreatic Cancer)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin 200 mg/m^2 or 400 mg/m^2 will be administered IV over 120 (± 15) minutes, q2w.</description>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
    <arm_group_label>Arm E (Metastatic Esophageal Cancer [mEC])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).</description>
    <arm_group_label>Arm C (Metastatic Pancreatic Cancer)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/m^2 will be administered IV over 120 (± 5) minutes q2w.</description>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
    <arm_group_label>Arm E (Metastatic Esophageal Cancer [mEC])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m^2) twice daily on Days 1-4 of a 21-day cycle.</description>
    <arm_group_label>Arm B (Gastric Cancer)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be administered as 80 mg/m^2 IV over 120 minutes q3w (Group E2).</description>
    <arm_group_label>Arm E (Metastatic Esophageal Cancer [mEC])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vanucizumab</intervention_name>
    <description>Vanucizumab will be administered at a flat dose of 2000 mg IV q2w (Group D1).</description>
    <arm_group_label>Arm D (HCC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion criteria

          -  Measurable disease per RECIST v1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic and end organ function

          -  Resolution of any acute, clinically significant treatment-related toxicity from prior
             therapy to Grade less than or equal to (&lt;/=) 1 prior to study entry, with the
             exception of alopecia

          -  Ready to use reliable contraceptive procedures

        Inclusion Criteria Specific to HCC (Arm A and Arm D):

          -  Participants with advanced or metastatic and/or unresectable HCC

          -  The participant has disease that is not amenable to a curative approach

          -  No prior line of systemic therapy (includes participants who are sorafenib-naïve)

          -  Willing to undergo fresh liver biopsy if provided archival tissue was taken greater
             than (&gt;) 6 months from Cycle 1 Day 1

          -  Child-Pugh Score of up to B7

          -  Serum bilirubin &lt;/= 3 times upper limit of normal (x ULN)

          -  International normalized ratio (INR) and activated partial thromboplastin time (aPTT)
             &lt;/= 2 x ULN

          -  Albumin &gt;2.8 grams per deciliter (g/dL)

          -  Documented virology status of hepatitis, as confirmed by screening hepatitis B
             surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and/or
             anti-hepatitis C virus (anti-HCV)

          -  Antiviral therapy per local standard-of-care if active hepatitis B virus (HBV)

        Inclusion Criteria Specific to Gastric Cancer (Arm B)

          -  Histologically or cytologically confirmed locally advanced or metastatic
             adenocarcinoma of the stomach or GEJ in participants who have not received prior
             systemic therapy for metastatic disease

          -  Absence of HER2 expression documented as in situ hybridization (ISH) negative on
             previously collected and assessed tumor tissue upon initial diagnosis of disease

        Inclusion criteria specific to metastatic pancreatic cancer (Arm C)

          -  Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas

          -  No previous radiotherapy, surgery, chemotherapy, or investigational therapy for the
             treatment of metastatic disease

        Inclusion Criteria Specific to mEC (Arm E)

          -  Histologically or cytologically confirmed locally mEC or metastatic adenocarcinoma of
             the GEJ Siewert Classification Type I in participants who have not received prior
             systemic therapy for primary and metastatic disease or chemoradiation therapy for
             primary disease

          -  Absence of HER2 expression documented as ISH-negative on previously collected and
             assessed tumor tissue upon initial diagnosis of disease

          -  Willing to undergo biopsy if archival tissue is not available or if archival tissue
             was taken &gt;6 months from Cycle 1 Day 1

        Exclusion Criteria:

        General Exclusion Criteria

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites

          -  Uncontrolled tumor-related pain

          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy

          -  Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, cirrhosis, fatty liver, and inherited liver disease (exception for
             participants in Arm A and Arm D)

          -  Known primary central nervous system (CNS) malignancy or untreated or active CNS
             metastases

          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
             or other recombinant human antibodies

          -  Positive test for Human Immunodeficiency Virus (HIV)

          -  Active hepatitis B (chronic or acute), or hepatitis C (exception for participants in
             Arm A and Arm D)

          -  Active tuberculosis

          -  Severe infections within 4 weeks prior to Day 1

          -  Signs or symptoms of significant infection within 2 weeks prior to Day 1

          -  Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1

          -  Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac
             disease (Class II or greater), myocardial infarction within 3 months prior to Day 1,
             unstable arrhythmias, or unstable angina

          -  History of stroke, reversible ischemic neurological defect or transient ischemic
             attack within 6 months prior to Day 1

          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study

          -  Any serious medical condition or abnormality in clinical laboratory tests that, in
             the investigators judgment, precludes the participants safe participation in and
             completion of the study

          -  Malignancies other than pancreatic carcinoma within 2 years prior to study start,
             with the exception of those with a negligible risk of metastasis or death (e.g.,
             expected 5-year OS &gt;90%) treated with expected curative outcome (such as adequately
             treated carcinoma in situ of the cervix, basal or squamous cell skin cancer,
             localized prostate cancer treated surgically with curative intent, ductal carcinoma
             in situ treated surgically with curative intent)

        Exclusion Criteria Related to Medications

          -  Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4),
             anti-programmed death-1 (anti-PD-1), or anti-programmed death ligand-1 (anti-PD-L1)
             therapeutic antibody

          -  Treatment with systemic immunostimulatory agents within 6 weeks or five half-lives of
             the drug, whichever is longer, prior to screening

          -  Treatment with systemic corticosteroids or other immunosuppressive medications
             (including but not limited to prednisone, cyclophosphamide, azathioprine,
             methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2
             weeks prior to Cycle 1, Day 1

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

          -  Participants with prior allogeneic bone marrow transplantation or prior solid organ
             transplantation

          -  Known allergies to oxaliplatin (or other platinum agents), leucovorin, 5-FU,
             nab-paclitaxel (or other taxanes) or gemcitabine

        Bevacizumab and Vanucizumab-Specific Exclusions (Arms A, B, and D)

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 3 days prior to the first dose of bevacizumab or vanucizumab

          -  History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation,
             or intra-abdominal abscess within 6 months prior to Day 1

          -  History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction
             within 6 months prior to Day 1 of Cycle 1

          -  Clinical signs or symptoms of GI obstruction or requirement for routine parenteral
             hydration, parenteral nutrition, or tube feeding

          -  Evidence of abdominal free air that is not explained by paracentesis or recent
             surgical procedure

          -  Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture

          -  Proteinuria, as demonstrated by urine dipstick or &gt; 1.0 g of protein in a 24-hour
             urine collection

          -  Metastatic disease that involves major airways or blood vessels, or centrally located
             mediastinal tumor masses of large volume. HCC participants (Arm A and D) with
             vascular invasion of the portal or hepatic veins may be enrolled

          -  History of intra-abdominal inflammatory process within 6 months prior to Day 1 of
             Cycle 1

          -  Radiotherapy within 28 days and abdominal/pelvic radiotherapy within 60 days prior to
             Day 1 of Cycle 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 of Cycle 1

          -  Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID)

        Exclusions specific to Arms A and D (HCC)

          -  Participants with untreated or incompletely treated varices with bleeding or
             high-risk for bleeding

          -  Treatment with any HCV anti-viral therapy within 4 weeks prior to Cycle 1 Day 1

          -  Moderate or severe ascites

          -  Hepatic encephalopathy

        Exclusions Specific to Arm E (Metastatic Esophageal Cancer)

          -  HER2 expression as defined by ISH positive and/or 3+ by immunohistochemistry

          -  Prior chemotherapy treatment, including radio-sensitization in pre- and
             post-operative settings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO30140 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helen Diller Fam Comp Can Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Inst.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>March 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
